Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, it develops its engEx Platform to expand upon the innate properties of exosomes to design, engineer, and manufacture exosome therapeutic candidates. Codiak Biosciences utilizes its platform to generate a pipeline of engineered exosomes aimed at treating a range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases.
|HQ||Cambridge, MA, US||Map|
Net income (FY, 2020)
EBIT (FY, 2020)
Market capitalization (14-Jul-2021)
Closing stock price (14-Jul-2021)
|Company Name||Date||Deal Size|
|Codiak Securities Corporation|
Codiak Biosciences has 167 Twitter Followers. The number of followers has increased 3.7% month over month and increased 13.3% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Codiak Biosciences founded?
Codiak Biosciences was founded in 2015.
Who are Codiak Biosciences key executives?
Codiak Biosciences's key executives are Douglas E. Williams, Linda C. Bain and Nicole Barna.
How many employees does Codiak Biosciences have?
Codiak Biosciences has 101 employees.
What is Codiak Biosciences revenue?
Latest Codiak Biosciences annual revenue is $2.9 m.
What is Codiak Biosciences revenue per employee?
Latest Codiak Biosciences revenue per employee is $28.9 k.
Who are Codiak Biosciences competitors?
Competitors of Codiak Biosciences include Nimbus Therapeutics, Takeda Pharmaceutical and Aduro Biotech.
Where is Codiak Biosciences headquarters?
Codiak Biosciences headquarters is located at 35 Cambridgepark Dr #500, Cambridge.
Where are Codiak Biosciences offices?
Codiak Biosciences has an office in Cambridge.
How many offices does Codiak Biosciences have?
Codiak Biosciences has 1 office.
Receive alerts for 300+ data fields across thousands of companies